Join Life Science Washington Institute in May, for part two of our grant writing bootcamp to help demystify SBIR/STTR funding routes.
This series is for anyone interested in learning more about SBIR and STTR funding opportunities and those who want to effectively compete for these awards to develop and commercialize innovative technologies. The bootcamp serves as an “intro” to the SBIR/STTR programs. At the end of the series, participants will be equipped and prepared to submit a proposal for SBIR or STTR funding.
When: Part I April 21 – register here
Part II, May 11, Time: 12-1:30 pm PDT Workshop
Where: Part I – Hosted virtually only – you will receive login information after registration,
Part II is virtual
Sessions are NOT recorded.
Who Should Participate?: This bootcamp series is for anyone interested in learning more about SBIR and STTR funding opportunities, and for those who want to effectively compete for these awards to develop and commercialize innovative technologies.
Cost & Registration: The workshop is FREE! Register here for Part II.
Format: Two interactive sessions, weekly assignments to help you prepare to submit your proposal, and the opportunity to receive feedback on assignments throughout the bootcamp. At the end of the series, participants will be equipped to begin the process of preparing a proposal for SBIR or STTR funding. Richard Giersch will lead the bootcamp.
Free 1:1 consults available with Rich Giersch available for those who attend. Please email arcwa@lswinstitute.org to sign up for a consultation or with any questions.
Rich Giersch is Strategic Advisor for Entrepreneurship and Innovation to Life Science Washington Institute and a principal investigator on a $3.5MM STTR that networks 24 academic institutions and is focused on building the commercialization ecosystem for life science companies in the Southeast US. Additionally, he is Chairman of the Board for the Bioscience Association of West Virginia, and CEO of WV based Valtari Bio.
Rich has held Director level positions at two venture capital firms, was the chief operating officer of a biotech company in Research Triangle Park, North Carolina, and the Chief Science Officer for the New Jersey Center for Biomaterials at Rutgers University. He has helped companies secure over $100 million in federal funding, tax, and relocation incentives and written over $15M in successful SBIR/STTR applications.